Table 4 Comparison between patients receiving Enzalutamid and those receiving placebo on health-related quality of life by applying the Improved RIDIT analysis to data from Devlin et al. [14]
Placebo vs Enzalutamid | Improved RIDIT | Chi-square | |||||
|---|---|---|---|---|---|---|---|
Week 13 | \( {\hat{\pi}}^{-} \) | \( {\hat{\pi}}^0 \) | \( {\hat{\pi}}^{+} \) | ARR [95% CI] | Odds ordinal [95% CI] | PBH-value | PBH-value (a) |
Mobility | 0.218 | 0.602 | 0.181 | 0.036 [− 0.011; 0.082] | 1.12 [0.98; 1.47] | 0.254 | 0.319 (0.319) |
Self Care | 0.075 | 0.868 | 0.057 | 0.018 [−0.009; 0.045] | 1.31 [0.94; 1.83] | 0.167 | 0.450 (0.225) |
Usual Activities | 0.227 | 0.592 | 0.180 | 0.047 [0.000; 0.094] | 1.26 [1.04; 1.53] | 0.175 | 0.204 (0.068) |
Pain/Discomfort | 0.301 | 0.487 | 0.212 | 0.089 [0.037; 0.142] | 1.42 [1.21; 1.67] | 0.007 | 0.025 (0.005) |
Anxiety/Depression | 0.248 | 0.579 | 0.173 | 0.075 [0.027; 0.122] | 1.43 [1.19; 1.71] | 0.013 | 0.024 (0.006) |
Week 25 | |||||||
Mobility | 0.215 | 0.597 | 0.188 | 0.027 [−0.029; 0.082] | 1.14 [0.89; 1.47] | 0.257 | 0.582 (0.582) |
Self Care | 0.092 | 0.850 | 0.058 | 0.034 [0.001; 0.067] | 1.58 [1.11; 2.26] | 0.157 | 0.309 (0.103) |
Usual Activities | 0.223 | 0.616 | 0.161 | 0.062 [0.008; 0.116] | 1.39 [1.10; 1.75] | 0.124 | 0.104 (0.026) |
Pain/Discomfort | 0.296 | 0.498 | 0.206 | 0.091 [0.029; 0.153] | 1.44 [1.19; 1.75] | 0.033 | 0.080 (0.016) |
Anxiety/Depression | 0.223 | 0.607 | 0.170 | 0.053 [−0.002; 0.108] | 1.31 [1.04; 1.66] | 0.132 | 0.322 (0.161) |